Ranbaxy Laboratories Ltd (RANB.BO)
1 Apr 2015
MUMBAI - Sun Pharmaceutical Industries shares slumped 16 percent on Tuesday, heading towards their biggest ever fall in a day, after the drugmaker's warning that 2016 sales would be flat at best due to costs related to remediation work at its plants.
* Sun Pharma expects "sustainable growth trajectory" after 2016
MUMBAI, July 21 - Shares in India's Sun Pharmaceutical Industries slumped 16 percent, heading towards their biggest daily fall ever, after the drugmaker on Monday said it sees 2016 sales flat at best.
** Sun Pharmaceutical Industries may fall sharply, denting its premium valuations for near term
MUMBAI - India's largest drugmaker, Sun Pharmaceutical Industries Ltd , said on Monday its revenue in fiscal 2016 would be flat at best as it struggles to fix manufacturing problems at Ranbaxy Laboratories, which it bought last year.
* Says remedial action at Ranbaxy's plants "on track" (Adds managing director's comments from conference call)
MUMBAI, July 20 - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, said on Monday its fiscal 2016 revenue might decline or stay flat due to costs related to fixing manufacturing issues at Ranbaxy Laboratories, which it bought for $3.2 billion last year.
** Company hikes prices in unit Ranbaxy Laboratories' US-branded portfolio - Credit Suisse
** Sun Pharmaceutical Industries slumps as much as 10 pct to 869.10 rupees as of 0445 GMT, its lowest since Feb. 27
MUMBAI - Sun Pharmaceutical Industries Ltd, India's largest drugmaker by sales, reported fourth-quarter profit well below analysts' expectations, hit by costs related to integrating smaller rival Ranbaxy Laboratories Ltd.